The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
After months of decline we are starting to see a slow increase in covid19 numbers and we are still in summer, I hope this doesn't indicate a start of a return to lockdowns...
https://coronavirus.data.gov.uk/
SNG - get your skates on don't miss this next wave...
Article yesterday by Covid actuary mentions expectation that UK covid19 hospitalisations are expected to increase after decline has stopped...
Also, as of 12 May 2022, ECDC has reclassified Omicron sub-lineages BA.4 and BA.5 from variants of interest to variants of concern https://www.ecdc.europa.eu/en/news-events/epidemiological-update-sars-cov-2-omicron-sub-lineages-ba4-and-ba5
Anyone know when Synairgen will post their accounts at companies house, would be good to see the balance sheet, monthly burn rate and value of assets (drugs have a shelf life).
I am still a believer in SNG just think this situation is of their own making as the trial should not have been hampered by patients taking other drugs and someone's head should role for this.
Suspect we will need another cash call later this year unless someone takes the plunge (you can have the best drug in the world but as the big boys have shown, you need to get out there and shout about it - lesser drugs now have millions of sales globally)
I think we have all learnt a painful lesson from this, although I wouldn't give up hope yet. The world is now choosing to treat Covid as a common cold like virus and although the removal of free testing in the UK will lead to significantly lower daily infections being recorded we will be more prone to new variants going un-noticed.
Winter will be another telling time and I personally still believe the science behind Synairgen is good it's just the Sprinter trial was flawed based on the administration of other drugs. Short sightedness from Activ-2 as well but time will tell!
Just back from Germany and my wife has Covid for the second time along with numerous members of staff. Most people getting it now are triple vax'ed, this thing ain't going anywhere.
Think ACTIV-2 a bit premature in not pushing ahead with P3 trial.
Where there is war there is an opportunity.
I was listening yesterday and based on election status for a few large EU partners and the winter Olympics being over (China would have been pis*ed) the timing of this incursion was timed to perfection.
Size82 - Synairgen's focus has long been the USA, hence the first jobs advertised. I am not saying Sprinter results wouldn't have been a good thing, what I am saying is that the ultimate prize and why Polygon got involved was Activ2. Sprinter not performing has given them a significant buying opportunity at a reduced prize and they will get to 29.9% quick sticks...
Not sure how the 30% works but guess they could buy 10% in 1 day if they wanted to jump quickly from 29.9% to 39.9%???
There is an opportunity here but in the near term the Baltic states will be wanting NATO to sure up their defences.
Historically, Russia lost millions of troops helping Europe overcome Germany, this war makes no sense and will only lead to more death and destruction when we should be focusing on a green economy.
This will however, push western nations to remove dependencies on Russia for Oil and Gas but we really need OPEC to step up now and lower the price of oil before the West goes broke!
In the short term, get onto your council's we know you can mix 20% hydrogen with gas and most councils have incinerators that could be switched out to use DMG's and produce hydrogen!
With Russia invading the Ukraine and Synairgen releases poor Sprinter results, its not been a good week. That said Polygon's investment are providing a ray of hope and we need to cling on to that!
I'm pretty sure Polygon did their homework before investing so much and although positive Sprinter results would have been great, Activ-2 P3 positive results have always been the end game.
Fellow investors, hold on tight as the roller-coaster ride has only just begun!
Basically Polygon are a bit more astute than your average investor.
Most smaller holder saw the failure of the Sprinter trial as a reason to dump their shares, whereas Polygon read the detail and have considered that the reason behind the change in P2 vs P3 was the fact that other drugs were administered. This is not the case with Activ-2.
So you either believe Synairgen that this is why Sprinter didn't live up to expectations or you dump and run.
I have added...